Retrotope, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Los Altos Hills CA United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2015
NCT02445794
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Retrotope, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

Di-deuterated linoleic acid ethyl ester (3 trials)

linolic acid (1 trial)

Drugs in Phase 2 Trials (1)

rimabotulinumtoxinB (Myobloc) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 3)

Cerebellar Ataxia (Phase 3)

Friedreich Ataxia (Phase 3)

Neuroaxonal Dystrophies (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3